# US 2016/0256547 A1 · Stable Aqueous Formulations of Adalimumab

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256547 A1
- Document ID: US20160256547A1
- Status: Published application
- Kind: A1
- Application number: 15/155,982
- Filed: 2016-05-16
- Published: 2016-09-08
- Earliest claimed: 2012-09-07
- Assignees: Coherus Biosciences, Inc.
- Applicants: Coherus Biosciences, Inc.
- Inventors: Mark Manning; Robert W. Payne
- Web page: https://patentgrep.com/patent/US20160256547A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/39533: {against materials from animals}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- C07K 16/241: {Tumor Necrosis Factors}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.

## Claims

### Claim 1

A buffered aqueous pharmaceutical composition comprising:
(i) adalimumab;
(ii) buffer; and
(iii) stabilizer;
wherein the composition is free of both polyol and surfactant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the stabilizer is selected from the group consisting of an amino acid, a salt, EDTA and a metal ion.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the amino acid is selected from the group consisting of glycine, arginine and combinations thereof.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the salt is selected from the group consisting of sodium chloride and sodium sulfate.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the salt is, or includes, sodium sulfate.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the buffer contains no citrate and consists of histidine, succinate, or a combination thereof.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition has a concentration of adalimumab of 30 to 50 mg/ml.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the concentration of adalimumab is about 50 mg/ml.

### Claim 9 (depends on 6)

The composition of claim 6, wherein histidine is the sole buffer in the composition; the composition has osmolality of about 180 to 420 mOsM; the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml; and the dosage contains about 10 to 80 mg of adalimumab.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the dosage is about 40 mg and results in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer that comprises citrate.

### Claim 11

A buffered aqueous pharmaceutical composition comprising:
(i) adalimumab;
(ii) buffer consisting essentially of histidine, succinate, or both; and
(iii) a stabilizer, consisting essentially of:
(a) an amino acid selected from glycine, alanine, glutamate, arginine, methionine, and combinations thereof; or
(a) and (b), where (b) is sodium chloride, sodium sulfate or both;
wherein the composition is free of both polyol and surfactant.

### Claim 12 (depends on 11)

The composition of claim 11, comprising histidine as the sole buffer, and glycine.

### Claim 13 (depends on 11)

The composition of claim 11, comprising histidine as the sole buffer, and arginine.

### Claim 14 (depends on 11)

The composition of claim 11, wherein (b) is, or includes, sodium sulfate.

### Claim 15 (depends on 11)

The composition of claim 11, wherein (b) is, or includes, sodium chloride.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the composition has a concentration of adalimumab of 30 to 50 mg/ml.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the concentration of adalimumab is about 50 mg/ml.

### Claim 18 (depends on 11)

The composition of claim 11 having osmolality of about 180 to 420 mOsM; wherein the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml; and the dosage contains about 10 to 80 mg of adalimumab.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the dosage is about 40 mg and results in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer comprising citrate.

### Claim 20

An aqueous buffered pharmaceutical composition comprising adalimumab and a citrate-free buffer, wherein the composition is free of both polyol and surfactant.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the composition has a concentration of adalimumab of 30 to 50 mg/ml.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the concentration of adalimumab is about 50 mg/ml.

### Claim 23 (depends on 20)

The composition of claim 20 comprising: (i) adalimumab; (ii) buffer consisting solely of histidine, succinate, or combination thereof; and (iii) glycine, arginine or both.

### Claim 24 (depends on 23)

The composition of claim 23 further comprising a salt selected from sodium chloride and sodium sulfate.

### Claim 25 (depends on 23)

The composition of claim 23 having osmolality of about 180 to 420 mOsM; wherein the composition is suitable for administration to a subject as a single dosage; said composition having a concentration of adalimumab in the range of 30 to about 50 mg/ml; and the dosage contains about 10 to 80 mg of adalimumab.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the concentration of adalimumab is about 50 mg/ml.

### Claim 27 (depends on 25)

The composition of claim 25, wherein the dosage is about 40 mg and results in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer comprising citrate.
